51 results about "In vitro test" patented technology

The invention discloses a method and a system for testing corrosion fatigue of a bone implantation device under a pathological condition, and relates to the technical field of orthopedic medical device evaluation, and the method comprises the following steps: constructing a dynamic load spectrum database covering physiological and pathological states; in-vitro reproduction of a dynamic mechanical environment borne by the bone implantation instrument in physiological and pathological states is completed through a multi-axis servo system; and acquiring service state data of the bone implantation instrument, and analyzing the service state data of the bone implantation instrument to obtain coupling experiment data. According to the invention, the defects of single load mode and environment simulation distortion in the traditional test method are overcome, high-fidelity simulation and comprehensive monitoring of the corrosion fatigue behavior of the bone implantation device under the pathological condition are realized, the consistency of the in-vitro test result and the in-vivo actual service performance is improved, and the application prospect is wide. And a scientific and unified evaluation basis is provided for material screening, structure optimization and service life evaluation of different types of bone implantation instruments.

Many drugs useful in treating cancer are metabolized by CYP2C8 enzymes, by CYP3A4 enzymes, or both. The effects of concomitant administration of relacorilant and paclitaxel, a drug used to treat cancer that is a substrate for both CYP2C8 and CYP3A4, are disclosed herein.Relacorilant potently inhibited CYP2C8 and CYP3A4 in in vitro tests, indicating that co-administration of relacorilant and paclitaxel would increase paclitaxel plasma exposure more than 5-fold in vivo, requiring significant reductions in paclitaxel doses when co-administering paclitaxel with relacorilant.Surprisingly, paclitaxel plasma exposure increased only by about 80% instead of the expected more than 5-fold increase expected with concomitant relacorilant and paclitaxel administration. Applicant discloses safe methods of co-administering relacorilant and paclitaxel by reducing the dose of paclitaxel to about half the paclitaxel dose used when paclitaxel is administered alone. Relacorilant and such reduced doses of paclitaxel may be co-administered to treat cancer, e.g., ovarian or pancreatic cancer.

Relacorilant is useful in the treatment of hypercortisolism and cancer. Many drugs useful in treating hypercortisolism or cancer are metabolized by CYP2C9 enzymes. The effects of concomitant administration of relacorilant and a CYP2C9 substrate are disclosed herein.Relacorilant potently inhibited CYP2C9 in an in vitro test, indicating that co-administration of relacorilant and a CYP2C9 substrate would be expected to increase the CYP2C9 substrate plasma exposure more than five-fold in vivo. Significant reductions in CYP2C9 substrate doses would be expected to be required when administered with relacorilant.Surprisingly, no such increase in plasma exposure was seen in human studies. Applicant discloses that relacorilant may be safely co-administered with unmodified doses of a CYP2C9 substrate such as, e.g., tolbutamide, glimepiride, and glipizide. Relacorilant and unmodified doses of CYP2C9 substrate such as tolbutamide, glimepiride, and glipizide may be co-administered to treat hypercortisolism, or may be co-administered to a cancer patient.

The present invention provides a sunscreen composition comprising: (i) TiO2, (ii) ZnO, (iii) triacontanyl PVP, and (iv) VP / hexadecene copolymer, wherein the composition is an oil-in-water emulsion substantially free of low molecular weight, organic UV absorbers, the ratio of (iii):(iv) is less than one, and the composition provides an in vitro SPF as measured by the IN VITRO SPF TEST METHOD of at least 25. The composition is surprisingly low viscosity and provides a high SPF.

The invention belongs to the technical field of biological detection, and provides a multiple cell factor detection kit in macrophage polarization and a preparation method and application thereof, and the detection kit comprises a capture antibody, a detection antibody, a mixed protein standard substance, a diluent and a washing buffer solution. The capture system is used for preparing a capture antibody coupled with a fluorescence coding microsphere by coupling a biotinylated antibody with a fluorescence microsphere coated with biotin, and the detection system is used for preparing a fluorescence labeled antibody by coupling derivatized phycoerythrin PE-SMCC with a specific thioether bond of a sulfhydrylated antibody. The mixed protein standard substance adopts a freeze-drying protection system containing BSA, trehalose and the like. The single hole of the kit can synchronously detect multiple cell factors, the sample dosage is only 25 microliters, the kit is suitable for in-vitro tests of mouse mononuclear macrophage leukemia cell lines RAW264.7, compared with a traditional ELISA method, the efficiency is improved by 10 times, the cost is reduced, and the kit has the remarkable advantages of being high in throughput, wide in linear range and high in stability.

An ex vivo test system 10 is constituted of a fluid circuit that circulates a prescribed circulation liquid by simulating the blood circulation state of a human body, and comprises a circulation liquid maintenance unit 17 that maintains, in the same manner as the blood environment in vivo, chemical factors in the circulation liquid, which affect the performance evaluation of a test object S. The circulation liquid maintenance unit 17 comprises: a replenishing liquid unit 23 that maintains the chloride ion concentration and protein concentration of the circulation liquid at desired values by injecting a replenishing liquid composed of an electrolyte-free isotonic solution into the fluid circuit; and a carbon dioxide supply unit 24 that maintains the pH of the circulation liquid at a desired value by supplying carbon dioxide into the fluid circuit, the state of the circulation liquid being maintained while compensating for the effect of moisture loss during circulation of the circulation liquid.

The disclosure relates to formulations and methods for the in vitro testing of ocular irritants. It was discovered that adding an antioxidant formulation to in vitro ocular irritation tests, including for example, a biochemical ocular irritation test, a reconstituted human corneal epithelium (RhCE) ocular irritation test and an excised eye depth of injury (Dol) test, substantially reduces the rate of false positives without diminishing test sensitivity, resulting in more accurately predicting ocular irritancy of test substances. More particularly, the disclosed method employs relatively high physiologic concentrations of one or more antioxidants that are normally present in tears. In a variation, much higher concentrations of one or more antioxidants may provide protection against in vivo exposure to ocular irritants.

This invention relates to the field of medical device technology, and in particular to an in vitro testing phantom, in vitro testing system, and method for assessing the application accuracy of a robot system. The in vitro testing phantom includes a first phantom with a first positioning point for inserting a test specimen; and a second phantom adapted to the first phantom and having a second positioning point. After the first and second phantoms are installed, the relative positions of the first and second positioning points are determined, and the projections of the first and second positioning points relative to the same plane at least partially overlap. Its advantage lies in that the first and second positioning points can cooperate to form a channel through which the test specimen can pass, thereby testing the application accuracy of the robot system. Only by changing the shape and size of the second positioning point can the accuracy requirements for the test specimen be changed, thus expanding the application range of the testing phantom.

Systems, devices, kits, and methods are provided herein in the form of example embodiments that relate to calibration of medical devices. The medical devices can be sensors adapted to sense a biochemical attribute. The embodiments can be used to determine calibration information specific to an individual medical device. The embodiments can determine the calibration information by reference to one or more parameters obtained during manufacturing of the medical device. The embodiments can also determine the calibration information by reference to in vitro testing of the medical devices. The embodiments also apply to systems incorporating those medical devices in their use in the field. Also described are embodiments of modifications to surfaces of sensor substrates, such as through applied radiation and / or the creation of a well, to aid in the placement and / or sizing of a sensor element on the substrate.

The invention discloses an application of mulberone H in preparation of a medicine for treating or preventing PEDV (Porcine Epidemic Diarrhea Virus) infection. In-vitro test results prove that the mulberone H significantly inhibits the enzyme digestion activity of PEDV 3C-like protease, and further verifies that the mulberone H inhibits PEDV infected cells, so that the mulberone H can be used for preparing the medicine for preventing and treating PEDV. Besides, mulberone H, as a natural substance separated from mulberries, can be used as a feed additive for a long time so as to achieve the purpose of preventing epidemic diseases, does not cause generation of drug-resistant strains after long-term use, and does not have other toxic or side effects. The defects of immune failure possibly caused by vaccination, virus variation caused by use of antiviral drugs and the like are overcome.

This invention discloses a semi-sandwich structured ruthenium triphenylphosphine dithiocarboxylic acid complex with a simple preparation process and its applications. The complex has the structure shown in Figure (I), with the central ruthenium and... η 5 - Coordination with cyclopentadiene, triphenylphosphine, and dithiocarboxylic acid derivatives, wherein the dithiocarboxylic acid ligands are selected from ethyl xanthic acid, isopropyl xanthic acid, ... N,N Diethyldithiocarbamic acid, morpholine dithiocarbamic acid, and carbazole dithiocarbamic acid. This invention employs a simple one-step method of room temperature preparation and recrystallization purification using a ruthenium precursor and dithiocarbamic acid ligand. This method offers advantages such as readily available raw materials, mild reaction conditions, simple post-processing, and high yield. In vitro tests show that the complexes exhibit excellent anti-proliferative activity against non-small cell lung cancer A549 cells, significantly superior to cisplatin. The complexes demonstrate activity by reducing mitochondrial membrane potential, inducing intracellular reactive oxygen species accumulation, and arresting the cell cycle (G1 phase), leading to late apoptosis in A549 cells.

The present application provides a kind of nereid polypeptide antithrombotic preparation, belong to the technical field of biopharmaceuticals.The present application finds that nereid plasmin polypeptide can inhibit the reaction of thrombin and fibrinogen to generate fibrin, thereby inhibiting the blood clotting reaction through in vitro test.Nereid plasmin polypeptide is determined for in vitro anti-platelet aggregation activity, and the inhibition rate of 640 μg / ml nereid plasmin polypeptide for anti-platelet aggregation is 75.68%, close to the inhibition effect of 1 mg / ml aspirin.The present application finds that nereid plasmin polypeptide group has the pharmacodynamic effect of reducing the weight of thrombus and the ratio of thrombus weight and length through nereid plasmin polypeptide antithrombotic effect test, has good antithrombotic effect, and can be used as nereid polypeptide antithrombotic preparation.

A new, original and ornamental design for a recyclable in vitro test system, comprising a diagnostic unit and a diagnostic reagent which is convertible into a optically perceptible diagnostic product by bringing it into contact with a sample material, wherein a housing surrounds the diagnostic unit at least in sections; the accompanying drawings refer for the above specified recyclable in vitro test system; design 1: view 1 shows a top view of the in vitro test system; view 2 shows a bottom view of the in vitro test system; view 3 shows a side view of the in vitro test system; view 4 shows front view of the in vitro test system; view 5 shows a perspective view of the in vitro test system from an oblique front view; design 2: view 1 shows a top view of the in vitro test system; view 2 shows a bottom view of the in vitro test system; view 3 shows a side view of the in vitro test system; view 4 shows front view of the in vitro test system; view 5 shows a perspective view of the in vitro test system from an oblique front view.

The present application relates to the technical field of veterinary medicine preparation, and particularly relates to a water-soluble medicine gastro-resistant and enteric-coated granule, a preparation method and application thereof, the coated granule comprising: an inner core of at least one water-soluble medicine active ingredient, a coating layer coated outside the inner core; and the coating layer is formed by a composite coating material of hydrogenated palm oil and lipophilic hydrophobic nano active light calcium carbonate. The present application has the advantages that the nano calcium carbonate is used to form pores in the true stomach by acid reaction and to produce gas by saponification with fatty acids in the intestinal tract, so that the water-soluble medicine is efficiently protected in the rumen and rapidly and completely released in the intestinal tract. In vitro tests show that the effective release rate can reach more than 79%, which is significantly better than the traditional coating, and has a broad clinical application prospect.

This invention relates to the field of computational toxicology, and in particular to a precise method for comparing the consistency of animal and non-animal toxicity evaluation results. This method acquires in vivo baseline data from animals and in vitro test data from non-animals. It employs a dynamic time warping algorithm and radial basis function kernel function to construct correction coefficients and perform equivalent mapping to generate a converted sequence. Based on a binary classification mapping of toxicity thresholds, a confusion matrix is ​​constructed to calculate sensitivity, specificity, and predicted values. Each indicator is treated as an independent source of evidence, and the Mahalanobis distance is calculated using the covariance matrix to generate a basic probability allocation function. The D-S evidence theory combination rule is applied for fusion, and a secondary factor allocation is introduced when there is conflict. Finally, the result is compared with a preset threshold to determine the feasibility of substitution. This invention adaptively eliminates the nonlinear misalignment difference between in vivo and in vitro dose responses, providing an objective quantitative judgment standard for toxicological substitution verification.

The invention provides an isophorone dye derivative LYC-CF3 as well as a synthesis method and application thereof. The specific name of the isophorone dye derivative is (E)-4-(2-(3-(dicyanomethylene)-5, 5-dimethylcyclohex-1-ene-1-yl) vinyl)-2-(trifluoromethyl) phenyl trifluoromethanesulfonate, and the structural formula of the isophorone dye derivative is shown in the description. The invention also provides a synthesis method of the derivative LYC-CF3, and a fluorescence imaging experiment of the derivative LYC-CF3 on O2 <-> in PC-12 cells. Through verification of a fluorescence spectrum and a laser confocal microscope, the derivative LYC-CF3 has quick response to O2 <-> in an in-vitro test and cells and relatively remarkable fluorescence imaging capability. Therefore, LYC-CF3 can be used as a fluorescent probe for in-vitro detection of O2 <-> and detection of O2 <-> in cells.

The present disclosure provides a system, device, control method and storage medium for simulating physical characteristics of blood vessels. The method for simulating physical characteristics of blood vessels comprises determining blood vessel types of a lesion to be studied, collecting clinical medical data of the lesion blood vessels, performing isolated modeling on each blood vessel branch, setting initial reference values of the model, connecting the blood vessel model and the device for simulating physical characteristics of blood vessels to an in-vitro test device, operating the in-vitro test device based on the initial reference values, and calculating blood vessel resistance, compliance and test temperature in the blood vessel model in real time according to sensor collected data, and calculating differences between target values and corresponding measured values. The in-vitro test device is adjusted through a simulated neural feedback mechanism and a direct coordination mechanism of each blood vessel branch until the differences between the target values and the corresponding measured values meet predetermined conditions.

In recent years, in an attempt to identify new therapies and more accurate biomarkers for the early diagnosis and treatment of liver diseases, to date, no biomarkers exist that allow for a definitive determination of the prognosis of patients with hepatic fibrosis. The present invention relates to a panel of biomarkers for in vitro testing in the diagnosis of liver disease, particularly for clinical diagnosis, with an emphasis on in vitro tests for diagnosing diseases associated with fibrosis, such as the detection of hepatic fibrosis processes using non-invasive methods in patients, as well as in individuals without known liver disease.

The invention discloses an application of phellinus linteus in preparation of a medicine for treating or preventing PEDV (Porcine Epidemic Diarrhea Virus) infection. In-vitro test results prove that the phellinus linteus can significantly inhibit the enzyme digestion activity of PEDV 3C-like protease, and further verify that the phellinus linteus can inhibit PEDV infection cells, so that the phellinus linteus can be used for preparing the medicine for preventing and treating PEDV. Besides, the phellinus linteus ketone is an active component extracted from moraceae plants, belongs to a natural isopentene flavonoid compound, can be used as a feed additive for a long time so as to achieve the purpose of preventing epidemic diseases, does not cause generation of drug-resistant strains after being used for a long time, and does not have other toxic and side effects; the defects of immune failure possibly caused by vaccination, virus variation caused by use of antiviral drugs and the like are overcome.

The present invention provides a sunscreen composition comprising: (i) TiO2, (ii) ZnO, (iii) triacontanyl PVP, and (iv) VP / hexadecene copolymer, wherein the composition is an oil-in-water emulsion substantially free of low molecular weight, organic UV absorbers, the ratio of (iii):(iv) is less than one, and the composition provides an in vitro SPF as measured by the IN VITRO SPF TEST METHOD of at least 25. The composition is surprisingly low viscosity and provides a high SPF.

The application provides a use of a banana tissue endogenous hormone zeatin in resisting banana wilt, and belongs to the technical field of plant protection. The banana tissue endogenous hormone is zeatin, and experiments prove that in vitro tests (tissue culture bottles and greenhouses) of the zeatin or lutein show that the zeatin can effectively inhibit the growth of TR4 mycelium, exhibits good anti-banana wilt fungus activity, has a significant prevention and control effect on the banana wilt fungus (TR4), and does not affect the growth of seedlings. The application provides a new idea and method for preventing and controlling TR4, and lays a foundation for in-depth exploration of the prevention and control of the banana wilt disease TR4.

The invention relates to the field of biological medicine, in particular to a three-component platinum (IV) complex containing captopril (CTP) and valproic acid (VPA), a preparation method of the three-component platinum (IV) complex and application of the three-component platinum (IV) complex in preparation of anti-tumor proliferation and anti-metastasis drugs. The anti-tumor proliferation and anti-metastasis effects of the target compound are tested through in-vivo and in-vitro testing means, and the anti-tumor mechanism of the medicine is researched. Results prove that the compound has a remarkable anti-tumor capability, particularly has an excellent treatment effect on metastatic malignant tumors, is expected to provide a new candidate drug for clinical treatment of tumors, and provides a new direction for research and development of novel platinum drugs and anti-tumor metastasis drugs.

The advent of ultra-large libraries of drug-like compounds has significantly broadened the possibilities in structure-based virtual screening, accelerating the discovery and optimization of high-quality lead chemotypes for diverse clinical targets. We explored new chemical spaces using reactions of sulfur(VI) fluorides to create a combinatorial library consisting of several hundred million compounds. We screened this virtual library for Cannabinoid Type II receptor (CB2) antagonists in conjunction with a rationally designed antagonist, AM10257. The top-predicted compounds were then synthesized and tested in vitro for CB2 binding and functional antagonism, achieving an experimentally validated hit rate of 55%. Our findings demonstrate the effectiveness of reliable reactions, such as Sulfur Fluoride Exchange (SuFEx) reactions, for diversifying ultra-large chemical spaces and facilitating the discovery of new lead compounds for important biological targets.

The absence of regulatory T cells (Treg) may underlie disorders including but not limited to autoimmunity, dermatitis, periodontitis and even transplant rejection. Enhancing local numbers of Treg through in situ Treg expansion or induction is contemplated herein as a treatment option for these disorders. Current methods for in vivo Treg expansion are not Treg specific and are associated with many adverse side-effects. The data presented herein provides in vitro testing of a Treg-inducing microparticle providing a predictable controlled release for combinations of cytokines and drugs (e.g., IL-2, TGF-β, and / or rapamycin) resulting in targeted Treg migration. These controlled release microparticles are also capable of inducing FoxP3+ Treg in human cells in vitro suggesting that these compositions be developed into an in vivo Treg induction and expansion therapy.

A computational continuous glucose monitoring system is disclosed which integrates a biocompatible phosphorescence-based insertable sensor and a custom-designed phosphorescence imager (PI). This PI captures phosphorescence lifetime images of an insertable sensor through the skin where the lifetime of the emitted phosphorescence signal is modulated by the local concentration of glucose. The lifetime images acquired through the skin are processed by neural network-based models for misalignment-tolerant inference of glucose levels, accurately revealing normal, low (hypoglycemia) and high (hyperglycemia) concentration ranges. Using a 1-mm thick skin phantom mimicking the optical properties of human skin, in vitro testing of the PI using glucose-spiked samples yielded 88.8% inference accuracy, also showing resilience to random and unknown misalignments within a lateral distance of ~4.7 mm. Lateral misalignments beyond 5 mm prompted user intervention for re-alignment.

The present application relates to the technical field of probiotic preparation, and particularly relates to a gastroenteric probiotic granule and a preparation method and application thereof, the coated granule comprises: a probiotic core material, and a coating layer coated outside the core material; the coating layer is formed by a composite coating material of hydrogenated palm oil and stearic acid surface modified nano active calcium carbonate, wherein the stearic acid surface modified nano active calcium carbonate accounts for 50% to 60% of the total mass of the composite coating material, and the weight ratio of the coating layer to the core material is 20% to 25%. The present application utilizes hydrogenated palm oil to form a hydrophobic physical barrier, and simultaneously utilizes nano calcium carbonate to slowly neutralize acidity in gastric acid, generate bubbles to form a microenvironment buffer, and realize a dual synergistic protection mechanism of physical barrier and chemical buffer. In vitro tests show that the probiotic granule prepared by the present application has a survival rate of greater than or equal to 90% after being treated in artificial gastric juice for 2 hours, and a release rate of greater than or equal to 93% after being treated in artificial intestinal juice for 2 hours, which is significantly better than traditional coating technology, and has a broad industrial application prospect.

The utility model provides a head mold device for an in-vitro test, and relates to the technical field of instrument detection. The head mold device for in-vitro testing is suitable for testing an instrument to be tested, the instrument to be tested comprises at least one detection electrode, the head mold device comprises a head mold body, the head mold body is provided with a first cavity, a first lower opening and at least one first through hole, and the first lower opening and the first through hole are connected with the first cavity; the bionic brain is placed in the first cavity, the bionic brain has the same outer contour as the human brain, the bionic brain has electrical conductivity, and the at least one detection electrode is suitable for penetrating through the at least one first through hole and is connected with the bionic brain; the signal generation module is suitable for generating a plurality of modulation test signals; the first ends of the multiple transmission wires are connected with the signal generation module, and the second ends of the multiple transmission wires penetrate through the first lower opening and are connected with the bionic brain. The head mold device can improve the verification reliability of the effectiveness of the to-be-tested instrument.

The invention belongs to the field of medical treatment, and discloses an application of 11-MT in medicine preparation. The medicine refers to a medicine for treating acute B lymphocytic leukemia. Researches show that 11-MT shows the following advantages in treatment of acute B lymphocytic leukemia: in an in-vitro test, 11-MT significantly promotes apoptosis of BALL-1 cells and shows dose dependence, 11-MT significantly promotes generation of ROS in the BALL-1 cells and shows dose dependence, 11-MT can cause DNA damage of the BALL-1 cells and shows dose dependence, and in an in-vivo test, 11-MT can significantly promote apoptosis of the BALL-1 cells and shows dose dependence. The 11-MT has a regulating effect on specific organ lesions, shows good repairing and protecting effects, can recover multiple serum biochemical indexes abnormally increased due to tumor load to a normal level, and can well reduce tumor cell infiltration.

The invention aims to disclose a preparation method and application of a biological fluorescent probe for detecting heavy metal silver ions. Silver is a high-toxicity heavy metal pollutant, excessive release in the environment and long-term accumulation in a living body can cause serious influence on an ecological system and human health. In recent years, a small organic molecule-based fluorescent sensing system and a nano fluorescent sensing system have gradually detected silver ions, but the design method is often complicated in synthesis method and is not suitable for a physiological environment or cannot distinguish other metal ions. Compared with other fluorescent probes, the biological fluorescent probe is widely concerned by researchers due to excellent biocompatibility, low cytotoxicity and excellent recognition capability. Dansyl chloride (DNSCI) is used as a luminous group for polypeptide modification to obtain a novel biological fluorescent probe, and both optical tests and in-vitro tests show that the probe can realize accurate recognition of Ag < + >.